:::

學術成果

:::
搜尋
年至

年至

月至



  • 關鍵字搜尋
  • 第 1 頁 / 共 1 頁
    1. [上一頁]
    2. 1
    3. [下一頁]
    研討會論文
    學年度會議期間著作著作人
    1012012/07/26
    2012/07/28
    Hsu C, Ou DL, Shiau CW, Fan HH, Liao SC, Lin YY, Hsu CH, Cheng AL.,2012,The roles of growth arrest DNA damage-inducible gene 45γ (GADD45γ) expression in sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells. ,Tenth Annual Meeting of Japanese Society of Medical Oncology.,Osaka, Japan.,2012/07/26-2012/07/28 (SCI)歐大諒
    1012012/07/26
    2012/07/28
    Ou DL, Hsu C, Lee BS, Chang YC, Cheng YC, Cheng AL.,2012,Exploring the anti-tumor efficacy of combination therapy with inhibitors targeting the insulin-like growth factor (IGF) and PI3K/AKT/mTOR signaling pathways for hepatocellular carcinoma (HCC).,Tenth Annual Meeting of Japanese Society of Medical Oncology.,Osaka, Japan.,2012/07/26-2012/07/28 (SCI)歐大諒
    1012012/05/09
    2012/05/12
    Ou DL, Fan HH, Hsu C, Cheng AL, Hsu CY, Shiau CW.,2012,Design and synthesis of GADD45β agonists for sorafenib-resistance hepatocellular carcinoma cells. ,AACR Special Conference on Molecularly Targeted Therapy: Mechanisms of Resistance.,San Diego, CA,2012/05/09-2012/05/12 (SCI)歐大諒
    1002011/10/15
    2011/10/18
    Hsu C, Ou DL, Chang YC, Cheng YC, Cheng AL,2011,Searching for mediators of sorafenib resistance in hepatocellular carcinoma by genomic approaches: The case of cyclin E1.,2011 Translation of the Cancer Genome,San Francisco, CA,2011/10/15-2011/10/18 (SCI)歐大諒
    1002011/09/23
    2011/09/27
    Ou DL, Lee BS, Chang YC, Shen YC, Hsu C, Cheng A,2011,Activation of Checkpoint Kinase 2 (Chk2) Contributes to the Antitumor Synergy Between IGF1 Receptor Kinase Inhibitor NVP-AEW541 and Sunitinib in Hepatocellular Carcinoma. ,2011 European Multidisciplinary Cancer Congress,Stockholm, Sweden.,2011/09/23-2011/09/27 (SCI)歐大諒
    992010/11/16
    2010/11/19
    Ou DL, Hsu C, Huang YT, Shen YC, Lee BS, Cheng AL,2010,Potentiating the anti-tumor efficacy of molecular targeted therapy (MTT) for hepatocellular carcinoma (HCC) by inhibiting the insulin-like growth factor (IGF) signaling pathway.,2010 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics,Berlin, Germany.,2010/11/16-2010/11/19 (SCI)歐大諒
    982009/11/15
    2009/11/19
    Fan HH, Yu SL, Ou DL, Shen YC, Huang YT, Hsu C, Cheng AL,2009,Searching for extracellular signal-regulated kinase (ERK)-independent molecular targets of sorafenib in hepatocellular carcinoma (HCC).,2009 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference,Boston, MA.,2009/11/15-2009/11/19 (SCI)歐大諒
    982009/11/15
    2009/11/19
    Ou DL, Shen YC, Chen KF, Wang CT, Fan HH, Yu SL, Hsu C, Cheng AL,2009,Induction of growth arrest DNA damage-inducible gene 45 beta (GADD45b) expression contributes to sorafenib-induced apoptosis in hepatocellular carcinoma (HCC) cells.,2009 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference,Boston, MA.,2009/11/15-2009/11/19 (SCI)歐大諒
    972008/00/00
    2008/00/00
    Ou DL, Shen YC, Yu SL, Lee WC, Yeh LC, Hsu C, Cheng AL,2008,Potential synergistic anti-tumor effects between sorafenib and the MEK inhibitor CI1040 in hepatocellular carcinoma (HCC). ,Proc Am Assoc Cancer Res,2008/00/00 (SCI)歐大諒
    第 1 頁 / 共 1 頁
    1. [上一頁]
    2. 1
    3. [下一頁]